Patients with the highest marker levels ( upper @th percentile for all markers ) not only had a poor prognosis ( hazard ratio -LSB- HR -RSB- = @ ; @ % confidence interval -LSB- CI -RSB- = @ to @ ; P < @ ) but also had a survival benefit from atrasentan ( HR = @ ; @ % CI = @ to @ ; median survival = @ -LSB- atrasentan -RSB- vs @ months -LSB- placebo -RSB- ; P interaction = @ ) .